Pay in 4 interest-free payments of $7.01 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication
Pharmacovigilance and signal detection FAERS semaglutide disproportionality (broad): A FAERS-based disproportionality analysis of semaglutide reports through mid-2023 identified multiple unexpected adverse event signals and explicitly notes that some signals were not mentioned in the drug insert, including polycystic ovaries. The analysis highlights typical spontaneous-reporting limitations (missing age, outcome data)
Patients with type 2 diabetes should be monitored closely, especially for changes in vision or worsening eye disease
(5) S (Study Design): Meta-analyses of RCTs or observational studies
Women may notice irregular periods, changes in cycle length, or occasionally anovulatory cycles
Most patients will start off on semaglutide because it was the first available on the market, is slightly less expensive, and the dual-hormone approach is not needed for everyone
US$ 20.38
US$ 28.09
US$ 27.66
